东诚药业：达肝素钠注射液增加规格获批上市

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular weight heparin product, Daltaparin Sodium Injection [1] Group 1 - The newly approved specification for Daltaparin Sodium Injection is aimed at enhancing the product's market offerings [1] - Daltaparin Sodium Injection is primarily used for the treatment of acute deep vein thrombosis and for preventing thrombus formation during hemodialysis and blood filtration in patients with acute or chronic renal failure [1] - The product also addresses unstable coronary artery diseases, including unstable angina and non-Q wave myocardial infarction, as well as preventing surgery-related thrombus formation [1]